🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  2. Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  3. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  4. BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  5. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  6. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  7. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. BNT111, LIBTAYO 350 mg concentrate for solution for infusion.

    BioNTech SE

    Melanoma (Stage III and IV)

    phase 2 small molecule active

    1 trial

  9. BNT116, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. BOTOX 100 Allergan Units Powder for Solution for Injection

    Disc Medicine

    postoperative pancreatic fistulas

    phase 2 small molecule active

    1 trial

  11. Bactrim 160 mg + 800 mg compresse, CHLORPHENAMINE MALEATE, ALLOPURINOL, BRUKINSA 80 mg hard capsules, DEXAMETHASONE PHOSPHATE, VENETOCLAX, VENETOCLAX, Gazyvaro 1,000 mg concentrate for solution for infusion., Lamivudina Mylan 150 mg compresse rivestite con film, VENETOCLAX, PARACETAMOL

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  12. Bavencio 20 mg/mL concentrate for solution for infusion

    Disc Medicine

    locally advanced urothelial cancer.

    phase 2 small molecule active

    1 trial

  13. Bendafolin 10 mg/ml Injektionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Xtandi - 40 mg film-coated tablets, Zirabev 25 mg/ml concentrate for solution for infusion, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, 5-Флуороурацил Ебеве 50 mg/ml концентрат за инжекционен и инфузионен разтвор., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Zirabev 25 mg/ml concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  14. Bendatax 6 mg/ ml, TAGRISSO 80 mg film-coated tablets, CISPLATIN, CARBOPLATIN, PEMETREXED, Cisplatin 1mg/ml Concentrate for Solution for Infusion, TAGRISSO 40 mg film-coated tablets, Armisarte 25 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, PACLITAXEL

    AstraZeneca AB

    Unresectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  16. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  17. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  18. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  19. Braftovi 75 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, Fianlimab, Braftovi 50 mg hard capsules

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  20. Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  22. Budigalimab, Telisotuzumab adizutecan, Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  23. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  24. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources